

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

<i>Application Number</i>	10/780,596
<i>Confirmation No.</i>	3367
<i>Filing Date</i>	February 18, 2004
<i>First Named Inventor</i>	Falotico, et al.
<i>Group Art Unit</i>	3738
<i>Examiner Name</i>	B. E. Pellegrino
<i>Attorney Docket Number</i>	CRD5065USNP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,368,736		Kaster	01-18-1983	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 4	<i>Application Number</i>	10/780,596
	<i>Confirmation No.</i>	3367
	<i>Filing Date</i>	February 18, 2004
	<i>First Named Inventor</i>	Falotico, et al.
	<i>Group Art Unit</i>	3738
	<i>Examiner Name</i>	B. E. Pellegrino
	<i>Attorney Docket Number</i>	CRD5065USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>BEUTLER, E., et al.</b> "Cladribine (2-Chlorodeoxyadenosine)", The Lancet (1992) Vol. 340, pp. 952-956	
		<b>CAMPBELL &amp; CAMPBELL</b> , "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture" (Table of Contents), Chapter 4, Volume 1, pp. 39-52 (1985)	
		<b>CAMPBELL and CAMPBELL</b> "Cell Biology of Smooth Muscle in Culture: Implications for Atherogenesis", Inter. Angio, 6, pp. 73-79 (1987)	
		<b>CARRERA, C., et al.</b> "Potent Toxicity of 2-Chlorodeoxyadenosine Toward Human Monocytes in Vitro and in Vito", J. Clinical Investigation Vol. 86 pp. 1480-1488 (1990)	
		<b>CARSON, D., et al.</b> "Specific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes", Blood, Vol. 62, No. 4, pp. 737-743 (1983) 62 pp. 737-743 (1983)	
		<b>CARSON, D., et al.</b> "Lymphocyte Dysfunction After DNA Damage by Toxic Oxygen Species", J. Exp. Medicine, Vol. 163 (March 1986) pp. 745-751	
		<b>CLOWES, A.W. et al.</b> , "Kinetics of Cellular Proliferation after Arterial Injury", Laboratory Investigation, Vol. 52, No. 6, pp. 611-616 (1985)	
		<b>EDELMAN, E., et al.</b> "Pathobiologic Responses to Stenting", American Journal of Cardiology, Vol. 81, Issue 7, Suppl. 1 (April 1998) pp. 4E-6E	
		<b>FISCHMAN, D., et al.</b> "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", The New England Journal of Medicine, Volume 331, pp. 496-501 (1994)	
		<b>FRANKLIN, S., et al.</b> "Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease, Vol. 4, No. 3 pp. 232-242 (March 1993)	
		<b>LANG R., et al.</b> "Effects of Okadaic Acid and ATPyS on Cell Length and CA <sup>2+</sup> -Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", Br. J. Pharmacol. 104, pp. 331-336 (1991)	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

<i>Application Number</i>	10/780,596
<i>Confirmation No.</i>	3367
<i>Filing Date</i>	February 18, 2004
<i>First Named Inventor</i>	Falotico, et al.
<i>Group Art Unit</i>	3738
<i>Examiner Name</i>	B. E. Pellegrino
<i>Attorney Docket Number</i>	CRD5065USNP

	<b>MAK and TOPOL, K., et al.</b> "Clinical Trials to Prevent Restenosis After Percutaneous Coronary Revascularization", Department of Cardiolg. Cleveland Clinical Foundation, Ohio pp. 255-288 (1991)	
	<b>MINTZ, G., et al.</b> "Limitations of Angiography in the Assessment of Plaque Distribution in Coronary Artery Disease", Circulation, Vol. 93 pp. 924-932 (1996)	
	<b>MINTZ, G., et al.</b> "Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study", Circulation, Vol. 94(1) pp. 35-43 (1996)	
	<b>MINTZ, G., et al.</b> "Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization", JACC, Vol. 27(7) pp. 1678 (1996)	
	<b>POMPA, J., et al.</b> "Clinical Trials of Restenosis After coronary Angioplasty", American Heart Association, Circulation, (1991) 84 pp. 1426-1436	
	<b>SERRUYS, P., et al.</b> "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized Double-Blind Placebo-Controlled Trial", American Heart Association, Circulation 88 (1993) pp. 1588-1601	
	<b>SERRUYS, P., et al.</b> "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", New England Journal of Medicine, Volume 33 pp.489-495 (1994)	
	<b>SERRUYS, P., et al.</b> "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation of the American Heart Association, Volume 93(3) pp. 412-422 (1996)	
	<b>SETO, S., et al.</b> "Mechanism of Doxygadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes", J. Clinical Investigation, Vol. 75 (February 1985) pp. 37-383	
	<b>TANAKA, H., et al.,</b> "Sustained Activation of Vascular Cells and Leukocytes In the Rabbit Aorta After Balloon Injury", Circulation, Vol. 88, pp. 1788-1803 (1993)	
	<b>TARDIF, J-C., et al.</b> "Probucol and Multivitamins in the Prevention of Restenosis After Coronary Angioplasty", New England Journal of Medicine, Volume 33, pp.365-372 (1997)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

<i>Application Number</i>	10/780,596
<i>Confirmation No.</i>	3367
<i>Filing Date</i>	February 18, 2004
<i>First Named Inventor</i>	Falotico, et al.
<i>Group Art Unit</i>	3738
<i>Examiner Name</i>	B. E. Pellegrino
<i>Attorney Docket Number</i>	CRD5065USNP

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.